跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
BCMA CAR-T cells
首页
药物
BCMA CAR-T cells
BCMA CAR-T cells
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN
EP 2836239 A1
申请人: US HEALTH
优先权: 2012
CN
EP
US
WO
46 件公开
BCMA-TARGETED CHIMERIC ANTIGEN RECEPTOR AS WELL AS PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
US 2020362048 A1
申请人: CELLULAR BIOMEDICINE GROUP HK LTD
优先权: 2018
CN
EP
US
WO
11 件公开
BCMA CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
EP 3806962 A1
申请人: NOVARTIS AG
优先权: 2018
CN
EP
US
WO
10 件公开
ENGINEERED IMMUNE CELL TARGETING BCMA AND USE THEREOF
EP 3967329 B1
申请人: GRACELL BIOSCIENCE SHANGHAI CO LTD
优先权: 2019
CN
EP
US
WO
10 件公开
CHIMERIC ANTIGEN RECEPTOR AND CAR-T CELLS THAT BIND BCMA
EP 3463396 A1
申请人: MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN HELMHOLTZ GEMEINSCHAFT
优先权: 2016
CN
EP
US
WO
9 件公开
ANTI-BCMA CHIMERIC ANTIGEN RECEPTORS
US 2020291087 A1
申请人: CARTESIAN THERAPEUTICS INC
优先权: 2019
CN
EP
US
WO
9 件公开
Chimeric antigen receptors targeting BCMA and methods of use thereof
US 11535677 B2
申请人: LEGEND BIOTECH USA INC
优先权: 2016
US
WO
8 件公开
BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA
EP 4255450 A1
申请人: JANSSEN BIOTECH INC
优先权: 2020
CN
EP
US
WO
7 件公开
EP 4698190 A1
申请人: LEGEND BIOTECH USA INC
优先权: 2023
EP
US
WO
6 件公开
EP 4426737 A1
申请人: JANSSEN BIOTECH INC
优先权: 2021
CN
EP
US
WO
4 件公开
US 20250269024 A1
申请人: LEGEND BIOTECH USA INC
优先权: 2024
US
WO
2 件公开
US 20250339527 A1
申请人: LEGEND BIOTECH USA INC
优先权: 2024
US
WO
2 件公开
Humanized BCMA antibody and BCMA-CAR-T cells
US 10927182 B2
申请人: CARIBOU BIOSCIENCES INC
优先权: 2020
US
7 件公开
US 2022356262 A1
申请人: PROMAB BIOTECHNOLOGIES INC
优先权: 2019
CN
US
WO
4 件公开
US 12528873 B2
申请人: PROMAB BIOTECHNOLOGIES INC
优先权: 2021
US
US 12173077 B2
申请人: PROMAB BIOTECHNOLOGIES INC
优先权: 2023
US
BCMA-TARGETED CAR-T CELL THERAPY OF MULTIPLE MYELOMA
EP 4055049 A1
申请人: JANSSEN BIOTECH INC
优先权: 2019
CN
EP
US
WO
6 件公开
US 2024156962 A1
申请人: LEGEND BIOTECH USA INC
优先权: 2023
US
第 1 / 8 页
上一页
下一页
药物
反馈